12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Oxytrol oxybutynin patch regulatory update

FDA approved Oxytrol oxybutynin patch from Actavis for OTC use in women to treat overactive bladder (OAB). Marketing partner Merck & Co. Inc. (NYSE:MRK, Whitehouse...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >